Expert perspectives on the use of daratumumab with RVd in patients with newly diagnosed multiple myeloma in the context of updates from the GRIFFIN study.
Videos
Expert hematologist-oncologist Ajay K. Nooka, MD, MPH, FACP, shares his perspective on the management of a woman newly diagnosed with multiple myeloma.
Tanios S. Bekaii-Saab, MD, FACP, discusses the differences between adagrasib and other KRAS inhibitors.
Sponsored in Part by AbbVie/Content Independently Developed by Targeted Oncology. Drs. Shaji Kumar and Jonathan Kaufman discuss how BCL-2 inhibitors fit into the different treatment options for multiple myeloma.
Sophia Kamran, MD, discusses the research supporting the use of trimodality therapy with immunotherapy for patients with urothelial cancer.
Sponsored in Part by AbbVie/Content Independently Developed by Targeted Oncology. An explanation of the focus on BCL-2 inhibitors versus the development of MCL-1 inhibitors for multiple myeloma treatment.
Andrew Wei, MBBS, PhD, discusses outcomes related to long-term survival in the QUAZAR AML-001 trial of oral azacitidine in patients with acute myeloid leukemia.
Hagop M. Kantarjian, MD, discusses the introduction of chimeric antigen receptor T cells and their impact on acute lymphoblastic leukemia.
Nino Balanchivadze, MD, FACP, discusses the rationale for evaluating toxicity based on race in the KEYNOTE-189 study.
Tanya Dorff, MD, discusses the recent findings from a phase 1 clinical trial which explored the use of chimeric antigen receptor T-cell therapy in patients with prostate cancer.
Sponsored in Part by AbbVie/Content Independently Developed by Targeted Oncology. Jonathan Kaufman, MD, describes clinical trials looking at venetoclax resistance, including the CANOVA study.
Sponsored in Part by AbbVie/Content Independently Developed by Targeted Oncology. Oncologists discuss the use of carfilzomib for multiple myeloma and their typical treatment regimens of choice.
Hagop M. Kantarjian, MD, discusses how the treatment landscape of acute lymphocytic leukemia compares to what it used to be.
John F. Seymour, MBBS, PhD, discusses the rationale for a post-hoc analysis of the phase 3 ELEVATE-RR trial comparing acalabrutinib and ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia.
Before closing out his discussion on transplant-ineligible multiple myeloma, Rafael Fonseca, MD, considers the future roles of CAR T-cell and bispecific antibody therapies.
Expert perspectives on two bispecific antibodies, teclistamab and talquetamab, that have been investigated in multiply relapsed multiple myeloma.
Shared insight on two novel CAR T-cell therapies, cilta-cel and ide-cel, that have been tested in multiply relapsed multiple myeloma.
Rafael Fonseca, MD, shares an overview of the treatment armamentarium for patients with relapsed/refractory multiple myeloma.
Practical advice on strategies to improve care for patients with transplant-ineligible multiple myeloma regarding induction and maintenance therapy, and aiming for deep and durable responses.
Expert perspectives on updated data from the MAIA trial in newly diagnosed transplant-ineligible multiple myeloma and how this can be applied to clinical practice.
Rafael Fonseca, MD, provides details on a patient case of transplant-ineligible multiple myeloma and reviews the selection of frontline triplet versus doublet therapy.
Lori A. Leslie, MD, discusses the impact that brexucabtagene autoleucel had on the treatment landscape for patients with relapsed or refractory mantle cell lymphoma.
Yuliya Mikheeva, MD, PhD, discusses the design of the phase 2 ANAPLAST-NEO study
Yelena Ginzburg, MD, discusses the prognosis and standard-of-care treatment in patients diagnosed with polycythemia vera.
Xiuning Le, MD, PhD, discusses counseling patients on the use of amivantamab-vmjw and mobocertinib and the sequencing of these drugs for patients with non–small cell lung cancer and an EGFR exon 20 insertion.
Lyudmila A. Bazhenova, MD, discusses targeted therapies for patients with BRAF-mutated non–small cell lung cancer.
In the third video of the series, Dr. Jyoti Malhotra from the Rutgers Cancer Institute of New Jersey shares expert insights on the benefits of using trilaciclib in clinical practice including considerations for chemotherapy treatment efficacy and patient quality of life. As of May 1, 2022, Dr. Malhotra is no longer with Rutgers Cancer Institute; she is now affiliated with City of Hope.
Before closing out her discussion on novel therapy for EGFR exon 20–positive NSCLC, Zofia Piotrowska, MD, shares her hopes for future developments in care.
Practical advice regarding the selection and management of amivantamab or mobocertinib in patients diagnosed with EGFR exon 20–positive NSCLC.
Comprehensive insight on the two novel, targeted agents approved for the management of EGFR exon 20–positive NSCLC following frontline therapy.